Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Greil

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyL Gianni, C S Huang, D Egle, et al.
British Journal of Cancer|October 26, 2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patientsP Dubsky, J C Brase, R Jakesz, et al.
Leukemia Research|January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II studyJ Thaler, W Hilbe, U Apfelbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trialJ Ferdinandus, H Müller, C Damaschin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)G G Steger, R Greil, A Lang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneM Gnant, M Filipits, R Greil, et al.
ESMO Open|March 27, 2026
Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort studyF Moik, F Huemer, B Doleschal, et al.
Leukemia Research|March 7, 2003
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)T Kühr, S Burgstaller, U Apfelbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12M Gnant, B Mlineritsch, H Stoeger, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyL Gianni, C S Huang, D Egle, et al.
British Journal of Cancer|October 26, 2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patientsP Dubsky, J C Brase, R Jakesz, et al.
Leukemia Research|January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II studyJ Thaler, W Hilbe, U Apfelbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trialJ Ferdinandus, H Müller, C Damaschin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)G G Steger, R Greil, A Lang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneM Gnant, M Filipits, R Greil, et al.
ESMO Open|March 27, 2026
Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort studyF Moik, F Huemer, B Doleschal, et al.
Leukemia Research|March 7, 2003
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)T Kühr, S Burgstaller, U Apfelbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12M Gnant, B Mlineritsch, H Stoeger, et al.
Pageof 15